NCT05855811View on ClinicalTrials.gov

PREventing Second Cancers With DOSTARlimab

PHASE2RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

July 26, 2023

Primary Completion Date

July 26, 2028

Study Completion Date

March 26, 2029

Conditions
Recurrent CancerPrimary CancerSecond Cancer
Interventions
DRUG

Dostarlimab

Dostarlimab should initiated within 6 months after the end of treatment for FPC.

Trial Locations (5)

69008

RECRUITING

Centre Léon Bérard, Lyon

Unknown

RECRUITING

Centre François Baclesse, Caen

RECRUITING

Centre Jean Perrin, Clermont-Ferrand

RECRUITING

Institut Claudius Regaud, Toulouse

RECRUITING

Institut Gustave Roussy, Villejuif

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Centre Leon Berard

OTHER

NCT05855811 - PREventing Second Cancers With DOSTARlimab | Biotech Hunter | Biotech Hunter